Enabling mRNA Therapeutic Development Through Enhanced IVT Capping Efficiency

Codex® HiCap RNA Polymerase is a next-generation, engineered RNA polymerase designed to meet the rigorous demands of today’s mRNA-based vaccines and therapeutics. Unlike wild-type T7 (WT T7) RNA polymerase, Codex HiCap significantly reduces the formation of undesirable double-stranded RNA (dsRNA) byproducts, which are known to trigger unwanted immune responses and compromise mRNA quality. It also enables more efficient incorporation of commercially available cap analogs through co-transcriptional capping, resulting in in vitro transcription (IVT) products with exceptional yield, purity, and consistency.

This advanced polymerase not only enhances the safety and potency of therapeutic mRNAs but also improves process efficiency — helping reduce the time and cost associated with clinical development. In this paper, we examine how Codex HiCap RNA Polymerase supports the production of high-performance synthetic mRNA, paving the way for next-generation mRNA therapies.